Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AHPA comments on FDAAA

This article was originally published in The Tan Sheet

Executive Summary

The American Herbal Products Association encourages FDA to implement carefully Sec. 912 of the FDA Amendments Act so it does not discourage investigations of the safety, functional effects or health benefits of substances that may be added to foods, the trade group says in comments submitted Nov. 25. FDAAA Sec. 912 prohibits interstate commerce of foods with an added approved drug or licensed biological product which is the subject of publicly disclosed substantial clinical investigations. If read strictly, this provision could block the sale of new and some existing dietary supplements and food ingredients, experts warn (1"The Tan Sheet" Aug. 11, 2008, In Brief). However, AHPA argues that the section does not replace or amend the Dietary Supplement Health and Education Act and does not affect dietary supplements

Related Content

Comment on FDAAA provision





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts